Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Interferon alpha 1b Eye Drops for elderly patients with COVID-19
ChiCTR2000029989Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of recombinant human interferon alpha-1b in coronavirus disease 2019 (COVID-19) and viral pneumonia (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Arterial blood oxygen saturation, Time to clinical recovery and 3 more. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
recombinant human interferon alpha-1b
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on ChiCTR2000029989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029989.